This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Actavis urges appeals court to allow Alzheimer's drug 'hard switch'

By Richard Vanderford ( April 13, 2015, 20:05 GMT | Insight) -- A plan to withdraw an obsolete version of an Alzheimer's drug is legal, drug company Actavis argued, urging a federal appeals court to reverse a decision that blocked its plan to "hard switch" patients to a newer, still patent-protected treatment. The judges did not clearly indicate their thinking, but did question whether the strategy might run afoul of competition law.A plan to withdraw an obsolete version of an Alzheimer's drug is legal, drug company Actavis argued Monday, urging a federal appeals court to reverse a decision that blocked its plan to "hard switch" patients to a newer, still patent-protected treatment....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections